Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study

Raymond R. Townsend; Paolo Guarnieri; Christos Argyropoulos; Shira Blady; Carine M. Boustany-Kari; Kishor Devalaraja-Narashimha; Lori Morton; Amy K. Mottl; Uptal Patel; Matthew Palmer; Michael J. Ross; Lea Sarov-Blat; Kathryn Steinbugler; Katalin Susztak; Randy Luciano; Michael Ross; Pietro Canetta; Krik Campbell; Jonathan Hogan; Amy Mottl; Oliver Lenz; Harold Szerlip; Shweta Bansal; Chip Brosius; Jeffery Schelling; Salem Almaani; Matthias Kretzler; Tamara Isakova; Rupali Avasare; Richard Lafayette

doi:10.1016/j.kint.2019.09.020

Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study

Raymond R. Townsend^*, Paolo Guarnieri, Christos Argyropoulos, Shira Blady, Carine M. Boustany-Kari, Kishor Devalaraja-Narashimha, Lori Morton, Amy K. Mottl, Uptal Patel, Matthew Palmer, Michael J. Ross, Lea Sarov-Blat, Kathryn Steinbugler, Katalin Susztak, Randy Luciano, Michael Ross, Pietro Canetta, Krik Campbell, Jonathan Hogan, Amy MottlOliver Lenz, Harold Szerlip, Shweta Bansal, Chip Brosius, Jeffery Schelling, Salem Almaani, Matthias Kretzler, Tamara Isakova, Rupali Avasare, Richard Lafayette

^*Corresponding author for this work

Medicine, Nephrology Division

Research output: Contribution to journal › Editorial › peer-review

26 Scopus citations

Original language	English (US)
Pages (from-to)	10-13
Number of pages	4
Journal	Kidney international
Volume	97
Issue number	1
DOIs	https://doi.org/10.1016/j.kint.2019.09.020
State	Published - Jan 2020

Funding

This study is supported by GlaxoSmithKline, Regeneron, Boehringer-Ingelheim, and Gilead Biosciences. Although these funding sources contributed to the content of this work through scientists they employ, the final manuscript reflects the independent contributions of the authors listed. This study is supported by GlaxoSmithKline , Regeneron , Boehringer-Ingelheim , and Gilead Biosciences. Although these funding sources contributed to the content of this work through scientists they employ, the final manuscript reflects the independent contributions of the authors listed.

Keywords

diabetic nephropathy
gene expression
glomerulus
kidney biopsy

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.kint.2019.09.020

Cite this

Townsend, R. R., Guarnieri, P., Argyropoulos, C., Blady, S., Boustany-Kari, C. M., Devalaraja-Narashimha, K., Morton, L., Mottl, A. K., Patel, U., Palmer, M., Ross, M. J., Sarov-Blat, L., Steinbugler, K., Susztak, K., Luciano, R., Ross, M., Canetta, P., Campbell, K., Hogan, J., ... Lafayette, R. (2020). Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Kidney international, 97(1), 10-13. https://doi.org/10.1016/j.kint.2019.09.020

@article{4695554799fc4d66963d25b4e9566306,

title = "Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study",

keywords = "diabetic nephropathy, gene expression, glomerulus, kidney biopsy",

author = "Townsend, {Raymond R.} and Paolo Guarnieri and Christos Argyropoulos and Shira Blady and Boustany-Kari, {Carine M.} and Kishor Devalaraja-Narashimha and Lori Morton and Mottl, {Amy K.} and Uptal Patel and Matthew Palmer and Ross, {Michael J.} and Lea Sarov-Blat and Kathryn Steinbugler and Katalin Susztak and Randy Luciano and Michael Ross and Pietro Canetta and Krik Campbell and Jonathan Hogan and Amy Mottl and Oliver Lenz and Harold Szerlip and Shweta Bansal and Chip Brosius and Jeffery Schelling and Salem Almaani and Matthias Kretzler and Tamara Isakova and Rupali Avasare and Richard Lafayette",

note = "Funding Information: This study is supported by GlaxoSmithKline, Regeneron, Boehringer-Ingelheim, and Gilead Biosciences. Although these funding sources contributed to the content of this work through scientists they employ, the final manuscript reflects the independent contributions of the authors listed. Funding Information: This study is supported by GlaxoSmithKline , Regeneron , Boehringer-Ingelheim , and Gilead Biosciences. Although these funding sources contributed to the content of this work through scientists they employ, the final manuscript reflects the independent contributions of the authors listed. ",

year = "2020",

month = jan,

doi = "10.1016/j.kint.2019.09.020",

language = "English (US)",

volume = "97",

pages = "10--13",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "1",

}

Townsend, RR, Guarnieri, P, Argyropoulos, C, Blady, S, Boustany-Kari, CM, Devalaraja-Narashimha, K, Morton, L, Mottl, AK, Patel, U, Palmer, M, Ross, MJ, Sarov-Blat, L, Steinbugler, K, Susztak, K, Luciano, R, Ross, M, Canetta, P, Campbell, K, Hogan, J, Mottl, A, Lenz, O, Szerlip, H, Bansal, S, Brosius, C, Schelling, J, Almaani, S, Kretzler, M, Isakova, T, Avasare, R & Lafayette, R 2020, 'Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study', Kidney international, vol. 97, no. 1, pp. 10-13. https://doi.org/10.1016/j.kint.2019.09.020

TY - JOUR

T1 - Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study

AU - Townsend, Raymond R.

AU - Guarnieri, Paolo

AU - Argyropoulos, Christos

AU - Blady, Shira

AU - Boustany-Kari, Carine M.

AU - Devalaraja-Narashimha, Kishor

AU - Morton, Lori

AU - Mottl, Amy K.

AU - Patel, Uptal

AU - Palmer, Matthew

AU - Ross, Michael J.

AU - Sarov-Blat, Lea

AU - Steinbugler, Kathryn

AU - Susztak, Katalin

AU - Luciano, Randy

AU - Ross, Michael

AU - Canetta, Pietro

AU - Campbell, Krik

AU - Hogan, Jonathan

AU - Mottl, Amy

AU - Lenz, Oliver

AU - Szerlip, Harold

AU - Bansal, Shweta

AU - Brosius, Chip

AU - Schelling, Jeffery

AU - Almaani, Salem

AU - Kretzler, Matthias

AU - Isakova, Tamara

AU - Avasare, Rupali

AU - Lafayette, Richard

N1 - Funding Information: This study is supported by GlaxoSmithKline, Regeneron, Boehringer-Ingelheim, and Gilead Biosciences. Although these funding sources contributed to the content of this work through scientists they employ, the final manuscript reflects the independent contributions of the authors listed. Funding Information: This study is supported by GlaxoSmithKline , Regeneron , Boehringer-Ingelheim , and Gilead Biosciences. Although these funding sources contributed to the content of this work through scientists they employ, the final manuscript reflects the independent contributions of the authors listed.

PY - 2020/1

Y1 - 2020/1

KW - diabetic nephropathy

KW - gene expression

KW - glomerulus

KW - kidney biopsy

UR - http://www.scopus.com/inward/record.url?scp=85076747611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076747611&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2019.09.020

DO - 10.1016/j.kint.2019.09.020

M3 - Editorial

C2 - 31901339

AN - SCOPUS:85076747611

SN - 0085-2538

VL - 97

SP - 10

EP - 13

JO - Kidney international

JF - Kidney international

IS - 1

ER -

Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this